Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

Recruiting

Phase 2

Gemcitabine, Cisplatin, Cemiplimab, FianlimabGemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

Sponsor:

Columbia University

Code:

NCT06571708

Conditions

Bladder Cancer

Muscle-Invasive Bladder Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Gemcitabine

Cisplatin

Cemiplimab

Fianlimab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-04. This information was provided to ClinicalTrials.gov by Columbia University on 2025-09-02.